A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors

被引：0
|
作者：
Cho, Byoung Chul
Lu, Shun
Lee, Myung Ah
Song, Zhengbo
Park, John
Lim, Sun Min
Li, Ziming
Zhao, Jun
Richardson, Gary
Zhang, Yanqiao
Zhang, Jun
Liu, Anwen
Chen, Cheng
Wang, Jia
Lu, Jingtao
Rui, Haopeng
Chen, Qian
Wang, Hui
Zhang, Jing
Chen, Zhi Jian
Mok, Tony
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT117
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II study
    Xu, R-H.
    Xu, Y.
    Yan, D.
    Munster, P.
    Ruan, D.
    Deng, Y.
    Pan, H.
    Underhill, C. R.
    Richardson, G.
    Nordman, I.
    Lee, K-W.
    Wei, S.
    Li, X.
    Shan, J.
    Han, G.
    Henderson, S.
    Xie, X.
    Xiang, Z.
    Shi, Z.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S410 - S411
  • [42] KontRASt-01: Preliminary Safety and Efficacy of JDQ443+TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
    Negrao, M. V.
    Cassier, P. A.
    Solomon, B.
    Schuler, M.
    Rohrberg, K.
    Cresta, S.
    Dooms, C.
    Tan, D. S. W.
    Loong, H. H-F.
    Amatu, A.
    Assmann, K. Krueger
    Fairchild, L.
    Sansregret, L.
    Fan, L.
    Farago, A. F.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S117 - S118
  • [43] Sotorasib with panitumumab in chemotherapy-refractory KRAS G12C-mutated colorectal cancer: a phase 1b trial
    Kuboki Y.
    Fakih M.
    Strickler J.
    Yaeger R.
    Masuishi T.
    Kim E.J.
    Bestvina C.M.
    Kopetz S.
    Falchook G.S.
    Langer C.
    Krauss J.
    Puri S.
    Cardona P.
    Chan E.
    Varrieur T.
    Mukundan L.
    Anderson A.
    Tran Q.
    Hong D.S.
    Nature Medicine, 2024, 30 (1) : 265 - 270
  • [44] Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
    Govindan, R.
    Fakih, M. G.
    Price, T. J.
    Falchook, G. S.
    Desai, J.
    Kuo, J. C.
    Strickler, J. H.
    Krauss, J. C.
    Li, B. T.
    Denlinger, C. S.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P. K.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 163 - +
  • [45] The Use of Lung Adenocarcinoma Patient-Derived Xenografts and Organoids to Study GDP-KRAS G12C Inhibitor Resistance
    Rosen, J.
    Sacher, A.
    Pham, N. -A.
    Weiss, J.
    Li, Q.
    Koga, T.
    Tucker, S.
    Radulovich, N.
    Koers, A.
    Niedbala, M.
    Ross, S.
    Tsao, M. -S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S437 - S438
  • [46] Phase 1/2 study of FMC-376 an oral KRAS G12C dual inhibitor in participants with locally advanced unresectable or metastatic solid tumors (PROSPER).
    Keating, Anne Therese
    Papadopoulos, Kyriakos P.
    Hloros, Eleni
    Spira, Alexander I.
    McKean, William Bennion
    Krivoshik, Andrew Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Safety and Efficacy of D-1553 in Patients with KRAS G12C Mutated Non-Small Cell Lung Cancer: A Phase 1 Trial
    Lu, S.
    Jian, H.
    Zhang, Y.
    Song, Z.
    Zhao, Y.
    Wang, P.
    Jiang, L.
    Gong, Y.
    Zhou, J.
    Dong, X.
    Yang, N.
    Fang, J.
    Zhuang, W.
    Cang, S.
    Ma, R.
    Shi, J.
    Wu, P.
    Lu, J.
    Xiang, Z.
    Shi, Z.
    Zhang, L.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S11 - S11
  • [48] Efficacy and safety of glecirasib (JAB-21822) monotherapy and in combination with cetuximab in patients with KRAS G12C-mutated advanced colorectal cancer.
    Li, Jian
    Huang, Jing
    Ba, Yi
    Cao, Baoshan
    Luo, Suxia
    Li, Wenhua
    Song, Zhengbo
    Zhu, Liangjun
    Xiong, Jianping
    An, Guangyu
    Zhang, Yanqiao
    Li, Zhihua
    Li, Yongsheng
    Gu, Yanhong
    Li, Xingya
    Huang, Chenghui
    Fu, Qihan
    Hu, Changlu
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 191 - 191
  • [49] A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
    Zhou, C.
    Li, W.
    Song, Z.
    Zhang, Y.
    Zhang, Y.
    Huang, D.
    Yang, Z.
    Zhou, M.
    Mao, R.
    Huang, C.
    Li, X.
    Wang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1273
  • [50] MOONRAY-01, a phase 1 study of LY3962673, a potent, orally bioavailable, and selective KRAS G12D inhibitor in KRAS G12D-mutant solid tumors
    Lakhani, Nehal J.
    Melisi, Davide
    Subbiah, Vivek
    Ammakkanavar, Natraj Reddy
    O'Reilly, Eileen M.
    Cassier, Philippe Alexandre
    Wainberg, Zev A.
    Duffy, Austin G.
    Patnaik, Amita
    Fujiwara, Yutaka
    Oberstein, Paul Eliezer
    Garcia-Carbonero, Rocio
    Wright, Jennifer
    Lin, Aimee K.
    Li, Jian
    Axelson, Michael D.
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS845 - TPS845
12345